In contrast to monotherapy with a low-dose anti-PD-1 antibody (10 μg) that did not directly affect tumor growth, combined treatment with WNK463 completely blocked tumor growth (Fig. 6b) and showed a marked decrease in tumor weights (Fig. 6c). Here, PDCD1 is linked to neoplasm.